While the mechanism behind these clinical results keeps unclear, herein, we comprehensively analyzed the genetic and immunologic characteristics of CRC with KRAS mutation, and try to explore the mechanisms and potential predictive biomarkers, especially from the prospect of tumor immune microenvironment (TIME). This evidence concerns the gene KRAS and neoplasm.